本帖最后由 老马 于 2012-1-13 21:20 编辑 . G; A8 I4 t7 `. ~& I
( T0 w% t d: U V* C爱必妥和阿瓦斯丁的比较; N( T0 I# D! i; o
0 E) Y1 p+ j) C# j" K, Khttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
" N A7 A7 x4 }, y& H
" u; q8 F, }: F7 s: ^; k" m
2 ^: U! v3 r9 l9 w
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
0 n6 H: R" D U$ C$ M- h==================================================
; T7 @# I: C9 w9 k2 AOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
6 q7 M' _4 W' W+ }; fPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
}; k0 K/ N$ f6 VResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported." h6 n' {' H% T
|